Abstract. Over recent years, the study of magnesium homeostasis has greatly benefited from molecular genetic approaches that identified several new classes of magnesium transporters. These proteins demonstrate a diversity of structural properties and biophysical functions that often translate into a wide range of tissue-specific cellular activities. Among these novel channels, MagT1 has gained most of the attention, given its high selectivity for Mg 2+ and its possible involvement in cellular functions reaching far beyond magnesium homeostasis, as the latest findings seem to imply. Indeed, a signaling role for MagT1 has been proven in T lymphocytes, where Mg 2+ functions as a second messenger, coupling TCR activation to intracellular effectors. We herein review these intriguing results and discuss their potential implications for magnesium research, and ultimately for therapeutic opportunities. As our knowledge of magnesium advances, it becomes increasingly clear that a deeper understanding of magnesium homeostasis is the key for a deeper insight into relevant pathophysiological conditions, and their treatment.
The last decade has witnessed a renewed interest in the study of magnesium homeostasis thanks to the molecular genetic approaches that have contributed to the identification of several classes of magnesium transporters. The characterization of these proteins at the cellular level unveiled their modulation by hormones, growth factors and extracellular magnesium availability, and has consequently opened up new highways to understand how magnesium can regulate crucial cellular activities such as proliferation, metabolism and motility, to name just a few.
The first transporter to be identified and associated with intracellular magnesium homeostasis was the transient receptor potential melastatin-7 (TRPM7) channel, a ubiquitous transmembrane protein that was shown to be essential for cell survival and proliferation [1, 2] . TRPM7 displays an atypical alpha-kinase domain at the cytoplasmic C-terminus, which inspired the name "chanzyme" [3] . Shortly after the identification of TRPM7 as the channel responsible for magnesium homeostasis at the cellular level, mutations in the TRPM6 gene were discovered in patients with a rare genetic disease called hypomagnesemia with secondary hypocalcemia (HSH) [4, 5] . Such findings hailed TRPM6 as the gatekeeper of magnesium homeostasis at the systemic level, as confirmed by subsequent studies that illustrated its specialized function, i.e. the uptake of magnesium through the epithelial barrier in the intestine and kidney [6, 7] . Moreover, key regulatory factors controlling Mg homeostasis through TRPM6 were identified. In particular, the first magnesiotropic hormones ever described were EGF [8, 9] and estrogen [10, 11] . TRPM6 and TRPM7 are highly similar: they display an overall 52% identity at the amino acid level, while the putative pore-forming regions and the kinase domains share more than 80% and 75% of their sequence, respectively. It is well established that the two sister channel can form homo-and hetero-tetramers with distinct biophysical characteristics [12] . Although it remains arguable whether TRPM6 can function on its own, without concomitant TRPM7 expression [13, 14] , it is clear that the two channels are functionally non-redundant and play unique and indispensable biological roles despite their high degree of homology [15] . The unique combination of channel and kinase domains in TRPM6/7 channels raises intriguing, and still much debated, scenarios whereby cation channel activities could be intertwined with intracellular signaling in pathophysiological contexts. There are several indications that via the kinase domain, TRPM6/7 function could go beyond ion transport at the plasma membrane, by interaction and/phosphorylation of downstream targets in the intracellular compartment [7, 16] .
Alongside TRPM6 and 7, several other novel magnesium transporters have been identified by differential gene expression using microarray analysis of cells cultured in low-Mg 2+ medium; these include MagT, SLC41, ACDP, MMgT, NIPA, HIP14 and MagC proteins [17] . In the face of a large diversity of structural designs and biophysical properties, it has been demonstrated that some of them can effectively substitute for TRPM7 and drive magnesium influx to secure cell survival and proliferation [18] [19] [20] . This pleiotropy, analogous to that of calcium transport systems, probably arises from a different evolutive history, and testifies to the importance of magnesium homeostasis for crucial cellular functions.
Among the newly-identified magnesium transporters, MagT1 has received most of the scrutiny as it is the only known selective plasma membrane Mg 2+ channel, and is currently at center stage, as a recent paper published in Nature pointed to unexpected roles for this channel, reaching far beyond magnesium homeostasis [21] .
MagT1 was the first differentially regulated gene identified as dramatically upregulated in conditions of magnesium deficiency [22] . The MagT1 gene is located on human chromosome [23] . No further characterization of TUSC3 is presently available in the literature.
Magnesium transport systems seem to be highly species-and tissue-specific, and so is MagT1 expression. While in several mammalian cells MagT1 was upregulated in Mg 2+ -deprived conditions [22, 23] , Schweigel et al. [24, 25] reported that in ovine rumen epithelial cells, MagT1 expression is upregulated by extracellular Mg 2+ . We ourselves showed that in rodent mammary epithelial cells, MagT1 mRNA is not modulated by extracellular magnesium [26] . In all cases cited, expression and/or modulation of other magnesium transporters were concomitantly detected; therefore, it appears that cellular magnesium homeostasis results from a complex balance of the activities of several transport systems that can compensate for each other when needed. For instance, DT40 B lymphocytes express both MagT1 and TRPM7. Culturing these cells in Mg 2+ -free medium for 24 h resulted in increased MagT1 levels [19] . When TRPM7 expression is knocked down (TRPM7 -/-cells), normal culture conditions result in a growth arrest that can be rescued by Mg 2+ supplementation [2] . Interestingly, in TRPM7 -/-cells, a substantial increase in MagT1 levels was shown, especially when cells were deprived of extracellular magnesium; furthermore, overexpression of recombinant MagT1 in TRPM7
-/-cells partially rescued the ability of these cells to take up Mg 2+ , as well as their growth defect in the absence of Mg 2+ supplementation [19] . The authors concluded that when cells are sensing suboptimal Mg 2+ concentrations, either due to extracellular deficiency or to the absence of TRPM7, they respond by transcriptional upregulation of MagT1, increasing Mg 2+ uptake, in an effort to avoid intracellular Mg 2+ deficiency. The partial restoration of the growth phenotype implies that MagT1 is a potent transporter that can compensate the lack of the "master" regulator of Mg 2+ homeostasis, TRPM7. At this stage it could be concluded that, despite the diverse regulation of Mg 2+ and its transport machinery in various cell types, the MagT1 channel appears to be an integral component of Mg 2+ uptake with important implications for cell survival/proliferation/development. The recent paper by Li et al. [21] has added an intriguing twist to the story, by proposing a signaling role for S88 MagT1 and Mg 2+ in the immune system. Not only did the authors identify a MagT1 mutation associated with a rare, X-linked CD4 + T-cell immunodeficiency (idiopathic CD4 lymphocytopenia, ICL), but they were also able to demonstrate that MagT1 is an essential component in the T-cell-receptor (TCR)-associated lymphocyte activation process. Indeed, they show that upon TCR stimulation, MagT1 drives a transient Mg 2+ influx that is necessary for the subsequent Ca 2+ rise and downstream signaling. The Mg 2+ -dependent TCR-mediated T-cell activation is very convincingly delineated by showing that between Mg
2+
and Ca 2+ signals, a specific PLCγ1 activation occurs, and this event is impaired in ICL patients ( figure 2) . Activation of the same pathway was also found in epithelial cell lines upon stimulation with epidermal growth factor (EGF), which is known to cause a PLCγ1-dependent Ca 2+ influx analogous to that induced by TCR engagement. However, it was not proven conclusively that Mg 2+ influxes are driven by MagT1 in all tissues, as other magnesium transporters might be present. For example, it is well known that EGF increases Mg 2+ currents via TRPM6 in renal epithelial cells [9] . Nonetheless, the work by Li et al. [21] demonstrates that in T lymphocytes MagT1 is necessary and sufficient for the Mg 2+ influx required for optimal cell activation, as proven by silencing MagT1 expression in normal T-cells or reconstituting MagT1 expression in patients' lymphocytes.
In conclusion, the paper [21] provides convincing evidence for the long-sought role of magnesium as a second messenger. In T cells, magnesium appears to fulfil the three fundamental features that characterize a second messenger [27] : (1) its levels increase rapidly in response to a stimulus (TCR activation), (2) it alters the rate of one or more cellular processes (PLC␥1 activation and subsequent events), and (3) it exerts cell type-specific activity (B cells do not have the same requirement for MagT1-mediated Mg 2+ influxes, despite expressing the channel).
As underlined by Wu and Veillette [28] [28] ). the defects in T-cell activation in MagT1-deficient patients to a problem with Mg 2+ uptake, but we do not know whether other magnesium transporters are present, and if so, why they are not able to compensate for the absence of MagT1. Could it be that MagT1 has other -as yet unidentified -functions contributing to immunodeficiency?
Secondly, the differences found between B and T cells in response to activation could be explained simply by the different signaling machinery present in the two cell types. Alternatively, could transporters other than MagT1 mediate Mg 2+ influx in B cells? As already mentioned, DT40 B lymphocytes also express TRPM7 [1, 2] , and MagT1 can partially complement the TRPM7 -/-phenotype [19] , but what about the other way round?
Along the same line of reasoning, it will be interesting to determine whether and how cell types other than lymphocytes are affected by the absence of MagT1. Again, studies on the tissuespecific expression and modulation of all known magnesium transporters would greatly add to our knowledge, not only of cellular magnesium regulation, but also of associated critical signaling cascades. In particular, it appears imperative to check for the localization of MagT1 in absorptive epithelia and investigate its role in total body homeostasis. Moreover, for a complete understanding of the signaling role of magnesium, we need to elucidate the molecular details of the action of free magnesium on PLC␥1 activation and calcium levels in different cell types. For example, does magnesium affect PLC␥1 directly, or through other associated proteins, such as the Itk kinase in T cells?
Last, but not least, the relevance of these findings goes far beyond the understanding of magnesium homeostasis. The unexpected role of MagT1 and magnesium in the immune system might lead to new therapeutic opportunities to control excessive T-cell-mediated immune responses, such as those seen in human autoimmune diseases or in transplant rejection.
Undoubtedly these questions are going to puzzle and intrigue scientists and clinicians alike in the near future. We do hope that in the light of these novel findings, more interest will be paid to magnesium as a key determinant in important pathophysiological conditions, and ultimately this will catalyze new resources and energies for its study. We look forward to a proliferation of magnesium research.
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